neffy® (epinephrine nasal spray), is developed with Neurelis’ proprietary Intravail® Absorption-Enhancing Technology SAN DIEGO, CA — December 8, 2022 — ARS Pharmaceuticals, Inc., announced that the U.S. Food & Drug Administration (FDA) has accepted its New Drug Application (NDA) for neffy (previously referred to as ARS-1), for the emergency treatment of severe type I allergic […]
NEURELIS, VALTOCO, MYNEURELIS, PERSONALIZED SUPPORT FOR PATIENTS AND CARE PARTNERS, and the NEURELIS, VALTOCO, and MYNEURELIS logos are trademarks or registered marks of Neurelis, Inc.
Intravail, ProTek, and Hydrogel, and the Intravail, ProTek, and Hydrogel logos are trademarks or registered trademarks of Aegis Therapeutics, LLC. Aegis Therapeutics, LLC, is a wholly-owned subsidiary of Neurelis, Inc.
Tosymra is a registered trademark of Dr. Reddy’s Laboratories Limited.
Imitrex is a registered trademark of the GlaxoSmithKline group of companies.
Neffy is a trademark of ARS Pharmaceuticals, Inc.
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are about to enter a site containing information on Medical Affairs and Research that is intended for US healthcare professionals only. Please confirm you are a healthcare professional and you wish to proceed to the HCP-only site.
